<DOC>
	<DOC>NCT00712855</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and tolerability of escalating doses of mapatumumab in combination with sorafenib in subjects with advanced Hepatocellular Carcinoma who are positive for hepatitis B surface antigen or hepatitis C antibody.</brief_summary>
	<brief_title>A Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Moderate liver disease Test positive for hepatitis B surface antigen or hepatitis C antibody Locally advanced unresectable/untransplantable or metastatic hepatocellular carcinoma Age 18 years or older Received investigational (not yet approved by a regulatory authority) or noninvestigational agent to treat hepatocellular carcinoma. Received radiation therapy within 4 weeks before randomization Major surgery within 4 weeks before randomization Minor surgery within 2 weeks before randomization Systemic steroids within 1 week before randomization Hepatic encephalopathy, per the investigator's evaluation History of clinically significant gastrointestinal bleeding requiring procedural intervention within 4 weeks before enrollment History of any infection requiring hospitalization or antibiotics within 2 weeks before randomization Known brain or spinal cord metastases History of other cancers within 5 years before enrollment Pregnant or breastfeeding women Known HIV infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Liver Cancer</keyword>
</DOC>